Marseille, France

Bruno Buisson

This inventor holds 6 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents. Top assignee: Trophos. Active years: 2010-2016.

USPTO Granted Patents = 6 



Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2010-2016

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Bruno Buisson: Innovator in Cytoprotection

Introduction

Bruno Buisson is a notable inventor based in Marseille, France. He has made significant contributions to the field of cytoprotection, holding a total of 6 patents. His work focuses on developing innovative methods and compounds that enhance neuroprotection and cytoprotection.

Latest Patents

Among his latest patents, one is titled "Use of cholest-4-en-3-one derivatives for obtaining a cytoprotective drug." This invention relates to the use of cholest-4-en-3-one derivatives specifically for creating a cytoprotective drug, excluding neuroprotective applications. Another significant patent is "Method for providing neuroprotection," which outlines a method for administering a neuroprotective-effective amount of a compound to patients in need of neuroprotection.

Career Highlights

Bruno Buisson is currently associated with Trophos, a company dedicated to advancing therapeutic solutions. His innovative work has positioned him as a key figure in the development of cytoprotective drugs.

Collaborations

Bruno has collaborated with notable professionals in his field, including Thierry Bordet and Cyrille Drouot. These collaborations have further enhanced the impact of his research and inventions.

Conclusion

Bruno Buisson's contributions to the field of cytoprotection through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in neuroprotection and therapeutic solutions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…